Track topics on Twitter Track topics that are important to you
Thursday, December 1st 2016 at 3:00pm UTC SAN FRANCISCO–(BUSINESS WIRE)– Cofactor Genomics, a leader in a new class of RNA products for disease research and diagnostics, announced today that they have partnered with FLX Bio, a biopharmaceutical company focused on the discovery and development of novel immuno-oncology (IO) therapeutics, to develop a novel RNA-based IO …
Cet article Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis
Platform est apparu en premier sur EEI-BIOTECHFINANCES.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...